Institute for OneWorld Health nominated for the 2004 World Technology Awards

August 16, 2004

San Francisco, Calif. - Aug. 16, 2004 - The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., announced today that it has been nominated for this year's World Technology Awards in the category of Health & Medicine. The award is sponsored by the World Technology Network (WTN) and held in association with Nasdaq, Microsoft, TIME magazine, Science magazine, and CNN.

Nominees for the World Technology Awards are selected by their peers in recognition of innovative work that is deemed likely to have long-term significance. The 20 award categories range from biotechnology, space and energy to ethics, design and entertainment. Winners will be announced on Oct. 8 at the World Technology Awards gala ceremony at San Francisco City Hall following the two-day World Technology Summit, which brings together more than 700 WTN members representing more than 55 countries.

"We are honored to be recognized so highly for our work in drug development to address global health inequities," stated Victoria Hale, Ph.D., Founder and CEO of OneWorld Health. "We are gratified by the confidence our peers have in our ability to deliver on our goal to provide affordable new medicines for people in the developing world." OneWorld Health is in the final stages of a clinical trial to develop a new cure for visceral leishmaniasis (VL), a parasitic disease that kills approximately 200,000 people each year, mostly in the Indian subcontinent. The company will seek regulatory approval in India next year, and finalize distribution plans to make the drug, paromomycin, an affordable, safe therapy to cure VL.

The Institute for OneWorld Health, the first U.S. nonprofit pharmaceutical company develops new, affordable medicines for infectious diseases that disproportionately affect people in the developing world. OneWorld Health applies its entrepreneurial business model with a staff of experienced pharmaceutical scientists who identifies promising leads and drives development from pre-clinical studies to clinical trials through regulatory approval. The Institute for OneWorld Health, headquartered in San Francisco, Calif., is a tax-exempt 501(c) (3), U.S. corporation (www.oneworldhealth.org).

The World Technology Network is a London-headquartered organization that was created to "encourage serendipity" - happy accidents - amongst those individuals and companies deemed by their peers to be the most innovative in the science and technology world. WTN also publishes "World Technology Intelligence, a collection of insights-from-the-innovators, largely written by and about current WTN members, as well as "World Technology Reports" on more focused topics of interest. Central events in the WTN calendar include the annual World Technology Summit and World Technology Awards - the culmination of a global judging program through which new members are nominated and selected and by which the network grows and is refreshed. For more information please visit www.wtn.net
-end-


Institute for OneWorld Health

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.